Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-343. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-343 SCHEMBL31060361 | 1.00 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL12872816 | 0.94 | SYK (0.88) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3837515 | 0.92 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL13007740 | 0.91 | SYK (0.83) | SYKJAK2EGFRLCKLYN | |
| R-343 SCHEMBL14877115 | 0.90 | SYK (0.80) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL4232302 | 0.89 | SYK (0.87) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL1198156 | 0.87 | SYK (0.77) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3833116 | 0.85 | SYK (0.75) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3837612 | 0.85 | SYK (0.73) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL15343489 | 0.84 | SYK (0.72) | SYKJAK2EGFRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534286-B1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2009-12-09 | — | — | EP | claimed |
| US-20180064646-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180064646-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| EP-2768480-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE) -6-YL]-5-FLUORO-N2- [3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE | Rigel Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2215087-B1 | XINAFOATE SALT OF N4- (2,2-DIFLUORO-4H-BENZO [1,4] OXAZIN-3-ONE) - 6-YL] - 5-FLUORO-N2 - [3-(METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20130281446-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281446-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8486935-B2 | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486935-B2 | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130102596-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| EP-2215087-A2 | XINAFOATE SALT OF N4- (2,2-DIFLUORO-4H-BENZO [1,4] OXAZIN-3-ONE) - 6-YL] - 5-FLUORO-N2 - [3-(METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | Pfizer Limited (GB) | 2010-08-11 | — | — | EP | disclosed |
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. | 2009-11-26 | — | — | US | disclosed |
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. | 2009-11-26 | — | — | US | disclosed |
| WO-2009031011-A2 | XINAFOATE SALT OF N4-(2, 2-DIFLUORO-4H-BENZ0 [1,4] 0XAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3- (METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2, 4-PYRIMIDINEDIAMINE | PFIZER LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009031011-A2 | XINAFOATE SALT OF N4-(2, 2-DIFLUORO-4H-BENZ0 [1,4] 0XAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3- (METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2, 4-PYRIMIDINEDIAMINE | PFIZER LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2007111720-A2 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204232-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZ0 [1,4] OXAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3-(METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2,4-PYRIMIDINEDIAMINE | HRH4, P2RY10, KCNN4 | SYK 105/4885JAK2 38/4885EGFR 2524/4885 |
| US-20180064646-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | YTHDF1, YTHDF2, YTHDF3 | SYK 441/4885JAK2 166/4885EGFR 1222/4885 |
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | ABCB4, ABHD16A, SGMS1 | SYK 2642/4885JAK2 1458/4885EGFR 479/4885 |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, RET, HRAS | SYK 3090/4885JAK2 149/4885EGFR 524/4885 |
| US-20130102596-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE | YTHDF1, YTHDF2, YTHDF3 | SYK 441/4885JAK2 166/4885EGFR 1222/4885 |
| US-20130281446-A1 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | P2RY4, KCNN4, KCNJ4 | SYK 143/4885JAK2 95/4885EGFR 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.